Metformin and Angiogenesis in Cancer - Revisited
| Autor: | Hemasri Tokala, Omar Alkharabsheh, Nikolay V. Dimitrov, Joseph Kannarkatt |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Vascular Endothelial Growth Factor A
0301 basic medicine Oncology Drug Tumor angiogenesis Cancer Research medicine.medical_specialty endocrine system diseases Angiogenesis media_common.quotation_subject Angiogenesis Inhibitors 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine Diabetes mellitus Antineoplastic Combined Chemotherapy Protocols medicine Humans Therapeutic strategy Glycemic media_common Neovascularization Pathologic business.industry nutritional and metabolic diseases Cancer General Medicine medicine.disease Metformin 030104 developmental biology 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Oncology. 91:179-184 |
| ISSN: | 1423-0232 0030-2414 |
| Popis: | Several clinical studies demonstrated that diabetic patients treated with metformin were less likely to develop vascular complications, independent of glycemic control. It was also demonstrated that the large variety of metformin's vascular actions can be seen in nondiabetic conditions. Metformin has an interesting potential to treat vascular dysfunction and tumor angiogenesis in conditions beyond diabetes. Since metformin's use in cancer as a single antiangiogenic agent appears to be a therapeutic disappointment, the use of the drug as part of combination anticancer modality represents a therapeutic challenge. The normalization of vascular dysfunction as a new therapeutic strategy may provide better delivery of conventional anticancer agents to the tumor and disrupted tumor environment. In this review, we will outline the available information from the literature regarding metformin and tumor angiogenesis and suggest eventual experimental and clinical approaches. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|